Linked Life Data

12601544

Source:http://linkedlifedata.com/resource/pubmed/id/12601544

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2003-2-25
pubmed:abstractText
There is no consensus regarding the optimal chemotherapy for endometrial cancer patients, and a need for better chemotherapy is evident. Two individuals with recurrent metastatic endometrial cancer treated with docetaxel and carboplatin combination chemotherapy are presented here. Both cases showed objective response to the chemotherapy (one complete response and the other partial response); response duration was 7 and 18 months, respectively. One patient who achieved complete response is alive without disease for 12 months after recurrence. Adverse effects in this regimen were mild and tolerable. Docetaxel in combination with carboplatin may be active agents for patients with metastatic endometrial cancer.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1341-9625
pubmed:author
pubmed:issnType
Print
pubmed:volume
8
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
53-5
pubmed:dateRevised
2006-4-24
pubmed:meshHeading
pubmed:year
2003
pubmed:articleTitle
Docetaxel and carboplatin combination chemotherapy for recurrent endometrial cancer.
pubmed:affiliation
Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi- dori, Niigata 951-8510, Japan. yoichi@med.niigata-u.ac.jp
pubmed:publicationType
Journal Article, Case Reports